Will the Novo-Catalent merger be challenged under the new Trump administration? A former FTC policy director thinks so.

Adds Reuters report. Catalent (NYSE:CTLT) rose 2.2% amid reports that the European Union's antitrust regulator will likely ...

Pharma leaders hoping for a friendlier merger environment after the Trump administration grabs the keys to the White House ...

Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug ...

Pharmaceutical contract manufacturing is when a company hires a third-party to produce drugs for them. The report by ...

Baird has recently raised Catalent Inc (CTLT) stock to Outperform rating, as announced on November 16, 2023, according to Finviz. Earlier, on September 5, 2023, Argus had raised the stock from a Hold ...

Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed ...

European Union seeks input from rival pharmaceutical firms on Novo Holding $16.5 billion acquisition of Catalent.

The growing inclination for biologics and biosimilars is driving the sterile injectable contract manufacturing market.New York, USA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Market Overview: Polaris Market ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the ...

With a market cap of $10.7 billion, Catalent, Inc. (CTLT) is a leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products.

Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its ...